The outcome of a Competition and Markets Authority’s (CMA) investigation, published today (July 29), found that Advanz charged an excessive price for its liothyronine tablets, which are used to treat thyroid hormone deficiency.
Free to registered users
Register to gain full access to C+D and C+D Community content
Already registered?